Not medical advice. Retatrutide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Retatrutide is listed in our catalogue under “Metabolic / Fat Loss.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Retatrutide, research triple agonist of the GLP-1 / GIP / glucagon receptor system, with the largest body-composition effects reported in the incretin class.
Peer-reviewed literature typically discusses Retatrutide in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 1–12 mg subcutaneously (dose escalation protocol) · Once weekly subcutaneous injection · Dose-proportional PK; t½ ≈ 6 days; Tmax = 12–72 h; hepatic metabolism without CYP interaction; dose escalation: 1 mg → 2 mg → 4 mg → 8 mg → 12 mg over 20–24 weeks in clinical protocols. Phase 3 TRIUMPH-1 (obesity) reported in 2025; further TRIUMPH readouts (type 2 diabetes, cardiovascular/kidney outcomes) expected through 2026.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Retatrutide is an investigational triple agonist — it activates the GLP-1, GIP and glucagon receptors — developed by Eli Lilly and still in clinical trials (not approved anywhere). Retatrutide is the research-grade form of this retatrutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is not an approved medicine and is not for human use.
In published research retatrutide activates three receptors at once — GLP-1 and GIP (satiety, insulin secretion, adipose effects) plus glucagon (hepatic energy expenditure and liver-fat clearance). The triple mechanism is what distinguishes it from dual (tirzepatide) and single (semaglutide) agonists. These are research findings for the molecule, not human-use guidance; Retatrutide is supplied for research only.
No. Retatrutide is still in clinical trials and is not approved by the FDA, EMA, or any other regulator. Retatrutide is an unapproved, research-grade lyophilised powder supplied for laboratory research use only — not for human consumption.
Retatrutide is investigational; its safety is still being characterised in clinical trials and is not established for general use. Research-grade Retatrutide is not a sterile approved medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.
For laboratory preparation, concentration in mg/mL equals the vial mass in mg divided by the millilitres of diluent added — e.g. a 10 mg vial reconstituted with 1 mL of bacteriostatic water gives 10 mg/mL, or with 2 mL gives 5 mg/mL. Keep the reconstituted vial refrigerated at 1–6 °C and protected from light. This is preparation math only; New-U provides no human-use dosing guidance.
Semaglutide targets one receptor (GLP-1), Tirzepatide targets two (GLP-1 and GIP), and Retatrutide targets three (GLP-1, GIP, and glucagon). The glucagon arm is what drives the additional hepatic thermogenesis and liver-fat clearance that set Retatrutide apart in published research.
It does, but at the right intensity and in combination with GLP-1, glucagon receptor agonism stimulates hepatic energy expenditure and fat oxidation without significant net glucose elevation. The GLP-1 arm offsets any glycemic downside while the glucagon arm delivers unique energy-balance effects.
No. Retatrutide is supplied for in-vitro and preclinical research only and is not approved as a medicine in any jurisdiction.
Published research protocols use a step-up schedule from 1 mg weekly, doubling over several weeks to 2 mg, 4 mg, 8 mg, and ultimately 12 mg. The gradual escalation is designed to minimise GI signals as systems adapt to triple-receptor activation.
Across the published GLP-1 literature, withdrawal of a GLP-1 receptor agonist is consistently followed by the return of appetite and partial-to-substantial regain of lost weight, because the appetite and gastric-emptying effects depend on continued receptor activation. Retatrutide is a triple GIP/GLP-1/glucagon agonist still in clinical trials, so any such observations describe investigational or approved medicines in human studies. Retatrutide is an unapproved research-grade peptide supplied for laboratory research only and is not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside Retatrutide.
Primary literature and registries for Retatrutide, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: GGG Triple Agonist, GLP-1/GIP/Glucagon Receptor Triple Agonist, Tri-Agonist